CRF Will Host Scientific Meeting February 15-16, 2018 in New York City


The CTO Summit 2018 is a two-day course featuring the latest research, advanced techniques, and state-of-the-art technologies for chronic total occlusions. The agenda is now available online at:

This year’s conference will emphasize practical hands-on training and will feature twelve live case transmissions conducted by some of the world’s leading experts in CTO stenting. Sessions will cover the following topics:

  • Patient Selection and Procedural Basics
  • CTO PCI in Specific Patient Populations (Higher Risk CTO PCI Patient, Post-CABG Patients, Patients with Low EF)
  • Case-Based Complication Management


A complete blockage in the coronary artery lasting more than three months, or chronic total occlusion (CTO), has historically been one of the most challenging types of blockages to treat with an interventional procedure. This meeting is aimed at helping interventional cardiologists treat CTOs. With advanced techniques, leading practitioners of percutaneous coronary intervention (PCI) can achieve success rates greater than 90%.


February 15-16, 2018


New York Marriott Marquis

1535 Broadway

New York, NY


The course directors for the CTO Summit 2018 are:

Emmanouil S. Brilakis, MD, PhD

Minneapolis Heart Institute

Minneapolis, MN

J. Aaron Grantham, MD

University of Missouri Kansas City and Saint Luke's Mid America Heart Institute

Kansas City, MO

Dimitri Karmpaliotis, MD, PhD

NewYork-Presbyterian/Columbia University Medical Center

New York, NY

Martin B. Leon, MD

NewYork-Presbyterian/Columbia University Medical Center

New York, NY

Jeffrey W. Moses, MD

NewYork-Presbyterian/Columbia University Medical Center

New York, NY

Masahiko Ochiai, MD

Showa University/Northern Yokohama Hospital

Kanagawa, Japan

Gregg W. Stone, MD

NewYork-Presbyterian/Columbia University Medical Center

New York, NY

Gerald S. Werner, MD

Klinikum Darmstadt

Darmstadt, Germany


Media may apply for registration by emailing For those interested in covering remotely, reporters are eligible for access to CTO 360 which provides live and on-demand viewing of sessions.


The Cardiovascular Research Foundation (CRF) will hold a free seminar, “The Link Between Diabetes & Your Heart,” on Wednesday, February 7, 2018 in New York City. The seminar, part of a series of Mini-Med School seminars conducted by the CRF Women’s Heart Health Initiative, will focus on providing attendees a deeper understanding of diabetes and its connection with cardiovascular disease. Attendees will also learn about lifestyle changes they can make to reduce the risk for and delay the onset of diabetes and heart disease.

The program will include the following presentations from renowned experts in the field as well as Q&A session in which attendees will be able to ask questions:

Diabetes 101: Myths vs. Facts
Jacqueline Y. Lonier, MD
Adult Endocrinologist, Naomi Berrie Diabetes Center
Assistant Professor of Medicine, Columbia University Medical Center

Heart Health and Diabetes
Nisha Jhalani, MD

Director, CRF Women’s Heart Health Initiative
Director, Clinical and Educational Services, CIVT
NewYork-Presbyterian/Columbia University Medical Center

PAD and Diabetes
Sahil A. Parikh, MD
Director, Endovascular Services, CIVT
NewYork-Presbyterian/Columbia University Medical Center

Prevention: Tips for Taking Control
Courtney Melrose, MPH, RD, CDE
Registered Dietitian and Certified Diabetes Educator
Naomi Berrie Diabetes Center

Patient Perspectives
(Q&A and Panel Discussion)


The rate of people being diagnosed with diabetes and prediabetes is rising quickly and remain serious threats to the health of Americans. According to the CDC, 30.3 million Americans — 9.4 percent of the U.S. population — have diabetes; an increase from 29.1 million in 2014. Another 84.1 million have prediabetes.

People with diabetes are at significant risk for serious complications, especially heart disease and strokes. According to the AHA, adults with diabetes are two to four times more likely to die from heart disease than adults without diabetes.

This rapid rise in diabetes rates and its impact on the heart health inspired the CRF Women’s Heart Health Initiative to educate the public on this important subject and give attendees the tools they need to take better care of themselves and their loved ones.


Wednesday, February 7, 2018

5:30 PM – 7:00 PM


Pryor Cashman

7 Times Square

New York, NY 10036


To register, visit:


NEW YORK –January 29, 2018 –The Cardiovascular Research Foundation (CRF) is pleased to announce that the latest issue of Structural Heart: The Journal of the Heart Team is now available online.

“The first issue of Volume 2 includes a mix of review and original research articles covering topics such as aortic stenosis from a heart failure perspective to transcatheter mitral valve repair and replacement,” said Anthony N. DeMaria, MD, Editor-in-Chief of the Journal and the Judith and Jack White Chair in Cardiology and Founding Director of the Sulpizio Cardiovascular Center at the University of California, San Diego. “The issue also features our new Fellow and Early Career Structural Heart Forum. Organized by Dr. Kimberly Atianzar, the forum is meant to provide a home for the needs and perspectives of trainees and early career physicians in the field. In this first article, Dr. Atizanar explores pursuing an additional training year in structural heart disease. As fellows will make major contributions to the evolution of the discipline, we hope they will provide us with their unique perspectives in future issues.”

Structural Heart, the official journal of CRF, is led by a distinguished Editorial Board of recognized international experts in the field. The Journal is dedicated to disseminating the latest research and information to members of the Heart Team, as well as the wider medical community interested in structural heart disorders.

Volume 2, Issue 1 of Structural Heart features the following articles:

Editor’s Page

Of Awards and Rewards

A. N. DeMaria

Review Articles

Classical and Paradoxical Low-Flow Low-Gradient Aortic Stenosis: A Heart Failure Perspective

M. Garbi et al.

Time to Move to Earlier Intervention for Thoracic Aortic Aneurysm?

A.A. Gryaznov et al.

Role of Computed Tomography in Pre-Procedural Planning of Transcatheter Mitral Valve Replacement

W.L. Yu et al.

The Risk in Avoiding Risk: Optimizing Decision Making in Structural Heart Disease Interventions

M.M. Mokhles et al.

Fellow and Early Career Structural Heart Forum

Taking the Leap Towards an Additional Fellowship Year in Advanced Structural Heart Disease Training

K. Atianzar

Original Research

Transcatheter Annuloplasty for Mitral Regurgitation with an Adjustable Semi-Rigid Complete Ring: Initial Experience with the Millipede IRIS Device

J.H. Rogers et al.

Editorial: Round and Round the Mitral Valve We Go: The Quest for Effective Transcatheter Mitral Valve Repair

T.M. Nazif and V. Bapat

Elixhauser Comorbidity Score Is the Best Risk Score in Predicting Survival After Mitraclip Implantation

J.F. Velu et al.

Editorial: Risk Scores for Post-Mitraclip Prognostication in Contemporary U.S. Practice: Are We Fitting a Square Peg to a Snowflake Shaped Hole?

H. Gada

Severe Symptomatic Bicuspid and Tricuspid Aortic Stenosis in China: Characteristics and Outcomes of Transcatheter Aortic Valve Replacement with the Venus-A Valve

G. Song et al.

Intracardiac Echocardiography-Guided Device Closure of Non-PFO/ASD Shunts

B. Acheampong et al.

Pre-Procedural Imaging Modalities for Device Size Selection and Adaptive Nature of the Appendage in Patients Undergoing Percutaneous Left Atrial Appendage Closure

D.H.F. Chow et al.

Images in Structural Heart Disease

Transcatheter Aortic Valve-in-Valve Intervention with Simultaneous Stent Implantation for Coronary Protection

D. Tavano et al.

About CRF and Structural Heart

The Cardiovascular Research Foundation (CRF) is a nonprofit research and educational organization dedicated to helping doctors improve the survival and quality of life for people suffering from heart and vascular disease. For over 25 years, CRF has helped pioneer innovations in interventional cardiology and has educated doctors on the latest treatments for heart disease. For more information, visit

Structural Heart: The Journal of the Heart Team is the official journal of CRF. It is a unique, international, and peer-reviewed journal focusing on diagnosing and treating diseases of the heart valves, myocardium, and great vessels, as well as congenital heart disease, and shedding light on the importance of the Heart Team in this process. The journal covers topics such as transcatheter procedures, cardiovascular surgery, drug treatment, basic and translational science and imaging in structural heart disease, and innovation (new devices, therapies, and first-in-man). For more information, visit:

One Year Results from the REDUCE Trial Reported at TCT 2017

DENVER – November 1, 2017 – Results from the prospective, multicenter, randomized investigator-initiated REDUCE trial were reported today at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine.

The optimal duration of dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS) treated with a drug-eluting stent is still under debate. The potential benefits of long-term DAPT in avoiding thrombotic complications may be offset by a higher risk of major bleeding complications. Researchers hypothesized that a reduction in DAPT duration could be achieved without increasing the overall treatment risk, by using the COMBO dual therapy stent, a stent designed to foster early re-endothelialization using a luminal anti-CD34 antibody with antiproliferative abluminal sirolimus elution.

From June 2014 to May 2016, 1,496 patients with acute coronary syndrome and treated with the COMBO dual therapy stent were randomly assigned to either three months (N=751) or 12 months (N=745) of DAPT. Clinical follow-ups were scheduled at three, six, 12, and 24 months. The primary study endpoint was a composite of all-cause mortality, myocardial infarction, stent thrombosis (ST), stroke, target-vessel revascularization (TVR), and bleeding (BARC II, III, V) at twelve months.

The trial found no difference in the primary endpoint between three and 12 months DAPT (8.2% vs. 8.4%, Pnoninferiority<0.001; Psuperiority=0.88). Among the secondary endpoints, major bleeding rates were similar among the treatment arms (2.5% vs. 3.0%, P=0.54), with non-significantly different rates of overall mortality (1.9% vs. 0.8%, P=0.07), cardiac mortality (1.1% vs. 0.4%, P=0.13), and definite/probable ST (1.2 % vs. 0.4%, P=0.08), although the study was not powered to assess these individual endpoints.  

“The REDUCE trial shows that among ACS patients treated with a COMBO stent, three months of DAPT is non-inferior to 12 months of DAPT, and this is consistent for all pre-specified subgroups” said Harry Suryapranata, MD, PhD, Professor of Interventional Cardiology at Radboud University Medical Center in Nijmegen, The Netherlands. “Therefore, this strategy could be considered if needed, even in ACS population. Future larger trials are needed to further investigate and confirm the safety of short-term DAPT regimen in ACS patients in the era of new ADP antagonists and new generation DES.”

The REDUCE trial is an investigator-initiated study funded by OrbusNeich. Dr. Suryapranata reported to have no conflicting personal financial interests, however his institution did receive an unrestricted research grant from OrbusNeich.



1 2 1